De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade
Status: SUSPENDED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|ER-Negative Breast Cancer|PR-Negative Breast Cancer|Node-negative Breast Cancer
Interventions: DRUG: Pertuzumab and tratuzumab fixed dose combination|DRUG: Trastuzumab emtansine
Sponsor: Jules Bordet Institute
Collaborators: Breast International Group|Hoffmann-La Roche|International Drug Development Institute|Institut Curie